Drug Profile

STACT TREX1

Alternative Names: STACT-TREX1

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Actym Therapeutics
Class Antineoplastics; Gene therapies; Immunotherapies; MicroRNAs
Mechanism of Action RNA interference; Three prime repair exonuclease 1 expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Jan 2025 No recent reports of development identified for preclinical development in Cancer in USA (IV)
25 Jan 2023 Preclinical development is ongoing in USA (IV) (Actym Therapeutics pipeline, January 2023)
14 Feb 2022 Actym Therapeutics has patent protection for Salmonella Typhimurium (Attenuated) Checkpoint Therapy (STACT) platform in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com